Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Dóra Türk"'
Autor:
Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Publikováno v:
Cancers, Vol 14, Iss 10, p 2407 (2022)
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the
Externí odkaz:
https://doaj.org/article/a59970b185b4400398ff2c64091f80a3
Autor:
Katalin Goda, Yaprak Dönmez-Cakil, Szabolcs Tarapcsák, Gábor Szalóki, Dániel Szöllősi, Zahida Parveen, Dóra Türk, Gergely Szakács, Peter Chiba, Thomas Stockner
Publikováno v:
PLoS Genetics, Vol 16, Iss 10, p e1009016 (2020)
Several ABC exporters carry a degenerate nucleotide binding site (NBS) that is unable to hydrolyze ATP at a rate sufficient for sustaining transport activity. A hallmark of a degenerate NBS is the lack of the catalytic glutamate in the Walker B motif
Externí odkaz:
https://doaj.org/article/6c1ca807bfcd44ed89b7d40d5630c092
Autor:
Edit Szabó, Dóra Türk, Ágnes Telbisz, Nóra Kucsma, Tamás Horváth, Gergely Szakács, László Homolya, Balázs Sarkadi, György Várady
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190629 (2018)
ABC multidrug transporters are key players in cancer multidrug resistance and in general xenobiotic elimination, thus their functional assays provide important tools for research and diagnostic applications. In this study we have examined the potenti
Externí odkaz:
https://doaj.org/article/9464bd06305d48278d5000f204f0913c
Autor:
Gergely Szakács, József Tóvári, László Cervenak, Nóra Kucsma, Dóra Türk, Veronika F.S. Pape, Kornélia Szebényi, Szilárd Tóth, András Füredi
Supplementary Figure 1: MDR-selective toxicity of NSC297366 in additional MDR cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68443fa44c4682e40a6e723b9dd6976c
https://doi.org/10.1158/1535-7163.22508104.v1
https://doi.org/10.1158/1535-7163.22508104.v1
Autor:
Gergely Szakács, József Tóvári, László Cervenak, Nóra Kucsma, Dóra Türk, Veronika F.S. Pape, Kornélia Szebényi, Szilárd Tóth, András Füredi
Structure of the compounds analyzed in this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909a5e7a4010fa963291ae12275eb74a
https://doi.org/10.1158/1535-7163.22508092
https://doi.org/10.1158/1535-7163.22508092
Autor:
Gergely Szakács, Norbert Szoboszlai, Jozsef Tovari, Pál T. Szabó, Christina Streli, Beáta G. Vértessy, György Várady, Nóra Kucsma, Judit E. Szabó, Melinda Gera, Anikó Gaál, Veronika F.S. Pape, Szilárd Tóth, Dóra Türk, Mihály Cserepes
Supplementary tables and figures, supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e819c0db7a5bd45216d4aaf201c1b0d
https://doi.org/10.1158/0008-5472.22424827
https://doi.org/10.1158/0008-5472.22424827
Autor:
Gergely Szakács, Norbert Szoboszlai, Jozsef Tovari, Pál T. Szabó, Christina Streli, Beáta G. Vértessy, György Várady, Nóra Kucsma, Judit E. Szabó, Melinda Gera, Anikó Gaál, Veronika F.S. Pape, Szilárd Tóth, Dóra Türk, Mihály Cserepes
Clinical evidence shows that following initial response to treatment, drug-resistant cancer cells frequently evolve and, eventually, most tumors become resistant to all available therapies. We compiled a focused library consisting of >500 commerciall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3bfd0cd96c275f4f36becbac6d1fe4
https://doi.org/10.1158/0008-5472.c.6511876
https://doi.org/10.1158/0008-5472.c.6511876
Autor:
Gergely Szakács, Michael M. Gottesman, Henry M. Fales, Joseph A. Ludwig, Benjamin F. Chu, Matthew D. Hall, Dóra Türk
Supplementary Figures 1-3, Tables 1-3 from Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3019d4880e894e724a68a532f8ee9664
https://doi.org/10.1158/0008-5472.22383096
https://doi.org/10.1158/0008-5472.22383096
Autor:
Gergely Szakács, Michael M. Gottesman, Henry M. Fales, Joseph A. Ludwig, Benjamin F. Chu, Matthew D. Hall, Dóra Türk
There is a great need for the development of novel chemotherapeutic agents that overcome the emergence of multidrug resistance (MDR) in cancer. We catalogued the National Cancer Institute's DTP drug repository in search of compounds showing increased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cc03b4f46efe16525f3eee8a39d7594
https://doi.org/10.1158/0008-5472.c.6500421
https://doi.org/10.1158/0008-5472.c.6500421
Autor:
Adél Kárpáti, Mihály Cserepes, László Őrfi, Györgyi A. Nelhűbel, Zita Hegedűs, József Tóvári, Erzsébet Rásó, Judit Dobos, Bálint Szokol, Tamás Barbai, Balázs Szabó, Dóra Türk, Viktoria Laszlo, István Kenessey
Publikováno v:
Pathology and Oncology Research
Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although seve